A Phase II Study of GM-CSF [granulocyte/macrophage colony stimulating factors] (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2015
At a glance
- Drugs Rituximab (Primary) ; Sargramostim (Primary) ; Carmustine; Cytarabine; Etoposide; Filgrastim; Melphalan
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Oct 2010 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 04 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.